

Literature Review

Budesonide (EE or Other Oral
Conditions)

Medication	Title of Article	Pubmedlink
BUDESONIDE	A New Formulation of Oral Viscous Budesonide in Treating Paediatric Eosinophilic Oesophagitis: A Pilot Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=272536 60
BUDESONIDE	Oral viscous budesonide can be successfully delivered through a variety of vehicles to treat eosinophilic esophagitis in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270252 98
BUDESONIDE	Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274160 45
BUDESONIDE	Systemic secondary amyloidosis in a 70-year-old patient with Crohn's disease: treatment with oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=234788 07
BUDESONIDE	Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192299 88
BUDESONIDE	Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186186 76
BUDESONIDE	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278895 74
BUDESONIDE	A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.	https://www.ncbi.nlm.nih.gov/pubmed/?term=269210 83
BUDESONIDE	Oral budesonide therapy for ulcerative colitis: a topical tale.	https://www.ncbi.nlm.nih.gov/pubmed/?term=896443 0
BUDESONIDE	Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=280816 77
BUDESONIDE	Formulation of budesonide mouthwash for the treatment of oral chronic graft-versus-host disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254112 62
BUDESONIDE	Oral budesonide for induction of remission in ulcerative colitis. [Review][Update of Cochrane Database Syst Rev. 2010;(10):CD007698; PMID: 20927762]	https://www.ncbi.nlm.nih.gov/pubmed/?term=264977 19
BUDESONIDE	Adrenal Suppression in Children Treated With Oral Viscous Budesonide for Eosinophilic Esophagitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259500 88
BUDESONIDE	Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249075 02
BUDESONIDE	Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249031 31

Medication	Title of Article	Pubmedlink
BUDESONIDE	Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).	https://www.ncbi.nlm.nih.gov/pubmed/?term=254252 14
BUDESONIDE	Oral viscous budesonide as a first-line approach to esophageal stenosis in epidermolysis bullosa: an open-label trial in six children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251381 21
BUDESONIDE	Oral budesonide as a therapy for protein-losing enteropathy in children after the Fontan operation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248892 58
BUDESONIDE	Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=245341 42
BUDESONIDE	Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=240293 79
BUDESONIDE	Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=239034 76
BUDESONIDE	Eosinophilic esophagitis: treatment with oral viscous budesonide. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=230503 87
BUDESONIDE	Identification of budesonide metabolites in human urine after oral administration.	https://www.ncbi.nlm.nih.gov/pubmed/?term=225730 60
BUDESONIDE	Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles.	https://www.ncbi.nlm.nih.gov/pubmed/?term=223271 33
BUDESONIDE	Oral budesonide as a therapy for protein-losing enteropathy in patients having undergone Fontan palliation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=221291 95
BUDESONIDE	The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=217844 10
BUDESONIDE	Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=216605 39
BUDESONIDE	Oral viscous budesonide therapy in children with epidermolysis bullosa and proximal esophageal strictures.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215936 50
BUDESONIDE	An adult case of eosinophilic pyloric stenosis maintained on remission with oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214098 59
BUDESONIDE	Oral budesonide for induction of remission in ulcerative colitis. [Review][Update in Cochrane Database Syst Rev. 2015;10:CD007698; PMID: 26497719]	https://www.ncbi.nlm.nih.gov/pubmed/?term=209277 62
BUDESONIDE	Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204571 57
BUDESONIDE	Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201721 40

Medication	Title of Article	Pubmedlink
BUDESONIDE	Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations.	https://www.ncbi.nlm.nih.gov/pubmed/?term=196941 84
BUDESONIDE	Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192037 24
BUDESONIDE	Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190359 72
BUDESONIDE	Oral formulations of budesonide: a novel treatment for inflammatory bowel disease. [Review] [54 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=191802 63
BUDESONIDE	Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189268 26
BUDESONIDE	Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports.	https://www.ncbi.nlm.nih.gov/pubmed/?term=185856 05
BUDESONIDE	Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180485 73
BUDESONIDE	Localized eosinophilic ileitis with mastocytosis successfully treated with oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=179191 49
BUDESONIDE	Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=175812 66
BUDESONIDE	Oral budesonide in the treatment of chronic refractory pouchitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=174515 69
BUDESONIDE	A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps.	https://www.ncbi.nlm.nih.gov/pubmed/?term=166520 85
BUDESONIDE	Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=166338 90
BUDESONIDE	Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163903 49
BUDESONIDE	Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup.	https://www.ncbi.nlm.nih.gov/pubmed/?term=159425 11
BUDESONIDE	Oral budesonide therapy improves quality of life in patients with collagenous colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155493 26
BUDESONIDE	Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155102 33
BUDESONIDE	Oral budesonide in the management of Crohn's disease. [Review] [38 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=145190 35
BUDESONIDE	Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127374 44

Medication	Title of Article	Pubmedlink
BUDESONIDE	Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126436 18
BUDESONIDE	Budesonide: a novel treatment for oral chronic graft versus host disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126271 01
BUDESONIDE	A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126227 61
BUDESONIDE	Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=118157 67
BUDESONIDE	Oral budesonide approved for active Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117637 99
BUDESONIDE	Drug Points: Anaphylactic-like reaction associated with oral budesonide.	https://www.ncbi.nlm.nih.gov/pubmed/?term=110306 79
BUDESONIDE	Oral budesonide in the treatment of primary sclerosing cholangitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=110072 38
BUDESONIDE	Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=109239 38
BUDESONIDE	Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=106552 52
BUDESONIDE	Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma.	https://www.ncbi.nlm.nih.gov/pubmed/?term=105036 81
BUDESONIDE	Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=105000 75
BUDESONIDE	Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=961630 9
BUDESONIDE	Oral budesonide for lymphocytic colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=946825 8
BUDESONIDE	Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=966382 8
BUDESONIDE	Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=930150 0
BUDESONIDE	Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=916451 7
BUDESONIDE	A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=898807 0

Medication	Title of Article	Pubmedlink
BUDESONIDE	Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=896439 5
BUDESONIDE	Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=888945 9
BUDESONIDE	Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=853688 7
BUDESONIDE	Contact allergy to budesonide in an oral spray.	https://www.ncbi.nlm.nih.gov/pubmed/?term=760079 4
BUDESONIDE	Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=807852 9
BUDESONIDE	Oral budesonide for treatment of autoimmune chronic active hepatitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=769644 6
BUDESONIDE	Treatment of active Crohn's disease with an oral slow-release budesonide formulation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=850340 3
BUDESONIDE	Oral budesonide in active Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=816166 6